Viemed Healthcare (NASDAQ:VMD) President Sells $370,536.72 in Stock

Viemed Healthcare, Inc. (NASDAQ:VMD) President Michael Moore sold 40,232 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $9.21, for a total value of $370,536.72. Following the sale, the president owned 1,650,812 shares of the company’s stock, valued at $15,203,978.52. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Moore also recently made the following trade(s):

• On Friday, March 20th, Michael Moore sold 65,000 shares of Viemed Healthcare stock. The stock was sold at an average price of $8.77, for a total value of $570,050.00.
• On Wednesday, March 18th, Michael Moore sold 31,570 shares of Viemed Healthcare stock. The shares were sold at an average price of $9.42, for a total value of $297,389.40.

Viemed Healthcare Trading Down 5.5%

Shares of NASDAQ:VMD traded down $0.51 during trading on Friday, reaching $8.71. 703,686 shares of the company traded hands, compared to its average volume of 245,033. The company has a current ratio of 1.18, a quick ratio of 1.06 and a debt-to-equity ratio of 0.08. Viemed Healthcare, Inc. has a 52-week low of $5.93 and a 52-week high of $10.06. The firm has a market capitalization of $336.21 million, a price-to-earnings ratio of 23.54 and a beta of 1.23. The business’s fifty day moving average is $8.30 and its 200-day moving average is $7.37.

Viemed Healthcare (NASDAQ:VMD) last issued its earnings results on Wednesday, March 4th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. Viemed Healthcare had a net margin of 5.53% and a return on equity of 10.72%. The company had revenue of $76.18 million for the quarter, compared to the consensus estimate of $77.70 million.

Wall Street Analysts Forecast Growth

VMD has been the subject of several recent analyst reports. Wall Street Zen raised shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “hold (c)” rating on shares of Viemed Healthcare in a report on Monday, December 29th. Finally, Zacks Research upgraded Viemed Healthcare to a “hold” rating in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Institutional Investors Weigh In On Viemed Healthcare

Several institutional investors and hedge funds have recently modified their holdings of VMD. Invesco Ltd. boosted its stake in shares of Viemed Healthcare by 17.1% during the 4th quarter. Invesco Ltd. now owns 21,773 shares of the company’s stock valued at $162,000 after purchasing an additional 3,173 shares in the last quarter. NewEdge Advisors LLC bought a new position in Viemed Healthcare in the fourth quarter worth about $174,000. Millennium Management LLC lifted its holdings in Viemed Healthcare by 348.2% in the fourth quarter. Millennium Management LLC now owns 48,398 shares of the company’s stock worth $360,000 after buying an additional 37,600 shares during the period. Man Group plc lifted its holdings in Viemed Healthcare by 13.2% in the fourth quarter. Man Group plc now owns 63,394 shares of the company’s stock worth $471,000 after buying an additional 7,397 shares during the period. Finally, Expect Equity LLC boosted its position in Viemed Healthcare by 59.6% during the 4th quarter. Expect Equity LLC now owns 173,970 shares of the company’s stock valued at $1,293,000 after acquiring an additional 64,961 shares in the last quarter. 74.24% of the stock is owned by hedge funds and other institutional investors.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.